+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 733 Pages
  • November 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5229516
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes - Pipeline Review, H2 2020, provides an overview of the Type 1 Diabetes (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 4, 2, 8, 39, 31, 1, 123, 27 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 2, 2, 1, 35 and 5 molecules, respectively.

Type 1 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 1 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 1 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Metabolic Disorders)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

Type 1 Diabetes - Overview

Type 1 Diabetes - Therapeutics Development

Type 1 Diabetes - Therapeutics Assessment

Type 1 Diabetes - Companies Involved in Therapeutics Development

Type 1 Diabetes - Drug Profiles

Type 1 Diabetes - Dormant Projects

Type 1 Diabetes - Discontinued Products

Type 1 Diabetes - Product Development Milestones

Appendix

List of Tables
  • Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia SAS, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aerami Therapeutics, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ahead Therapeutics SL, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Akston Biosciences Corp, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Algiax Pharmaceuticals GmbH, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Allele Biotechnology and Pharmaceuticals Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Alpine Immune Sciences Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Altheia Science SRL, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ALTuCELL, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amarna Therapeutics BV, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AmideBio LLC, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Anokion SA, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aphios Corp, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Apodemus AB, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by APT Therapeutics Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aptamer Sciences Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Arecor Ltd, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ariddad Therapeutics SL, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Artery Therapeutics Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Atlantic Bio Sci LLC, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AVM Biotechnology LLC, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Avotres Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Beijing Advaccine Biotechnology Company Ltd, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biocon Ltd, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLingus AG, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Bioorg3.14 LLC, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biozeus Pharmaceutical SA, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BirchBioMed Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Bol Pharma, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Bopin (Shanghai) Biomedical Technology Co Ltd, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Boston Therapeutics Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Bristol-Myers Squibb Co, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BTB Pharma AB, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by CAR-T (Shanghai) Biotechnology Co Ltd, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Carlina Technologies SAS, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by CellTrans Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Chongqing Chenan BioPharm Co Ltd, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Compugen Ltd, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by TwotoBiotech Ltd, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Unicyte AG, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Valin Technologies Ltd, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ventria Bioscience, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Veralox Therapeutics Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Vertex Pharmaceuticals Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ViaCyte Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ViCapsys Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Virtici LLC, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by vTv Therapeutics Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XERIS Pharmaceuticals Inc, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XL-protein GmbH, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XOMA Corp, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Yichang Hec Changjiang Pharmaceutical Co Ltd, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Youngene Therapeutics Co Ltd, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Zealand Pharma AS, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H2 2020
  • Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Adocia SAS
  • Aerami Therapeutics
  • Ahead Therapeutics SL
  • Akston Biosciences Corp
  • Algiax Pharmaceuticals GmbH
  • Allele Biotechnology and Pharmaceuticals Inc
  • Alpine Immune Sciences Inc
  • Altheia Science SRL
  • ALTuCELL
  • Amarna Therapeutics BV
  • AmideBio LLC
  • Anokion SA
  • Aphios Corp
  • Apodemus AB
  • APT Therapeutics Inc
  • Aptamer Sciences Inc
  • Arecor Ltd
  • Ariddad Therapeutics SL
  • Artery Therapeutics Inc
  • AstraZeneca Plc
  • Atlantic Bio Sci LLC
  • AVM Biotechnology LLC
  • Avotres Inc
  • Axxam SpA
  • Beijing Advaccine Biotechnology Company Ltd
  • Beta-Cell NV
  • Biocon Ltd
  • BioLingus AG
  • Bioorg3.14 LLC
  • Biozeus Pharmaceutical SA
  • BirchBioMed Inc
  • Bol Pharma
  • Bopin (Shanghai) Biomedical Technology Co Ltd
  • Boston Therapeutics Inc
  • Bristol-Myers Squibb Co
  • BTB Pharma AB
  • Cancer Prevention Pharmaceuticals Inc
  • CAR-T (Shanghai) Biotechnology Co Ltd
  • Carlina Technologies SAS
  • CellTrans Inc
  • Chongqing Chenan BioPharm Co Ltd
  • Compugen Ltd
  • Cour Pharmaceuticals Development Co Inc
  • CRISPR Therapeutics AG
  • Curyx Bio Inc
  • CymaBay Therapeutics Inc
  • Daewoong Pharmaceutical Co Ltd
  • Dendright Pty Ltd
  • Diabetology (Products) Ltd
  • Diamyd Medical AB
  • Diasome Pharmaceuticals Inc
  • DiaVacs Inc
  • Dompe Farmaceutici SpA
  • Dualogics Corp
  • Eli Lilly and Co
  • Emerald Organic Products Inc
  • Endsulin LLC
  • Ensol Biosciences Inc
  • Enthera Srl
  • EpiVax Inc
  • Evotec SE
  • Fairbanks Pharmaceuticals Inc
  • FasCure Therapeutics LLC
  • Follicum AB
  • Ganli Pharmaceutical Co Ltd
  • Generex Biotechnology Corp
  • Genprex Inc
  • Geropharm
  • Gubra ApS
  • Hanmi Pharmaceuticals Co Ltd
  • Housey Pharmaceutical Research Laboratories LLC
  • Iltoo Pharma
  • ImCyse SA
  • Immunocore Ltd
  • ImmunoMolecular Therapeutics LLC
  • ImmusanT Inc
  • Innovimmune Biotherapeutics Inc
  • Inversago Pharma Inc
  • Islexa Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • JN Biosciences LLC
  • Johnson & Johnson
  • Jortan Pharmaceuticals Inc
  • Kadimastem Ltd
  • Kamada Ltd
  • Kiniksa Pharmaceuticals Ltd
  • Kriya Therapeutics Inc
  • Kunming Yinnuo Medical Technology Co. Ltd.
  • L2 Diagnostics LLC
  • Landos Biopharma Inc
  • Lannett Co Inc
  • Larix Bioscience LLC
  • Lexicon Pharmaceuticals Inc
  • MannKind Corp
  • Maruho Co Ltd
  • Medytox Inc
  • Mercia Pharma Inc
  • Merck & Co Inc
  • Metavant Sciences Ltd
  • MidaSol Therapeutics LP
  • Neovacs SA
  • NextCell Pharma AB
  • Novartis AG
  • Novo Nordisk AS
  • OneVax LLC
  • Op-T-Mune Inc
  • Oramed Pharmaceuticals Inc
  • Orgenesis Inc
  • Orion BioScience Inc
  • Otsuka Holdings Co Ltd
  • Pancryos AS
  • Pandion Therapeutics Inc
  • Panorama Research Inc
  • Paras Biopharmaceuticals Finland Oy
  • Parvus Therapeutics Inc
  • Pfizer Inc
  • PharmaCyte Biotech Inc
  • PolTREG Sp z o o
  • Polus Inc
  • Precigen Inc
  • Prometheon Pharma LLC
  • Protokinetix Inc
  • Protomer Technologies Inc
  • Provention Bio Inc
  • Purzer Pharmaceutical Co Ltd
  • Regenerative Medical Solutions Inc
  • REGiMMUNE Corp
  • Remd Biotherapeutics Inc
  • reMYND NV
  • Renova Therapeutics Inc
  • Repertoire Immune Medicines
  • Rezolute Inc
  • Rubius Therapeutics Inc
  • SAB Biotherapeutics Inc
  • Sahane Biotech Inc
  • Sanofi
  • Sensulin LLC
  • Seraxis Inc
  • Sernova Corp
  • Serpin Pharma LLC
  • Sihuan Pharmaceutical Holdings Group Ltd
  • SQZ Biotechnologies Co
  • Stelis Biopharma Pvt Ltd
  • Suntec Medical (Taiwan) Inc
  • SymbioCellTech LLC
  • Tetragenetics Inc
  • TherapyX Inc
  • Thermalin Inc
  • Toleranzia AB
  • Tolerion Inc
  • Tolerx, Inc. (Inactive)
  • Topas Therapeutics GmbH
  • Transgene Biotek Ltd
  • TwotoBiotech Ltd
  • Unicyte AG
  • Valin Technologies Ltd
  • Ventria Bioscience
  • Veralox Therapeutics Inc
  • Vertex Pharmaceuticals Inc
  • ViaCyte Inc
  • ViCapsys Inc
  • Virtici LLC
  • vTv Therapeutics Inc
  • XERIS Pharmaceuticals Inc
  • XL-protein GmbH
  • XOMA Corp
  • Yichang Hec Changjiang Pharmaceutical Co Ltd
  • Youngene Therapeutics Co Ltd
  • Zealand Pharma AS
  • Zhejiang Hisun Pharmaceutical Co Ltd